8-K: Hepion Pharmaceuticals CEO Departs, Separation Agreement Detailed

Hepion Pharmaceuticals, Inc. reports on the separation agreement with former CEO Dr. Kaouthar Lbiati, detailing severance payments and her resignation from the board.

Summary

• Hepion Pharmaceuticals, Inc. has entered into a separation agreement with its former CEO, Dr. Kaouthar Lbiati, effective April 13, 2026.
• The agreement includes a severance payment of $225,000 to Dr. Lbiati.
• She will also receive $30,625, representing the pro-rata portion of her potential cash bonus.
• Reimbursement for COBRA payments for a period of 6 months is also part of the agreement.
• Dr. Lbiati has agreed to a general release and confidentiality terms.
• In addition to her CEO role, Dr. Lbiati resigned as a director of the Company on April 13, 2026.
• Her resignation as CEO was previously disclosed on March 16, 2026, for personal reasons.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it details a standard executive separation process without immediate positive or negative operational implications.

Positives

• The company has reached a formal separation agreement with its former CEO, providing clarity on terms.
• The agreement includes a defined severance package, mitigating potential disputes.
• Confidentiality terms are included, which is standard and beneficial for the company.

Negatives

• The departure of the CEO, even for personal reasons, can indicate internal instability or challenges.
• The company is currently operating with an interim CEO, which may affect strategic continuity.

Risks

• Potential impact on ongoing research and development projects due to leadership transition.
• Uncertainty regarding the long-term strategic direction of the company without a permanent CEO.

Future Outlook

No specific future outlook or guidance is provided in this filing, which primarily details executive separation terms.

Management Comments

• Gary Stetz, Interim Chief Executive Officer, signed the report on behalf of Hepion Pharmaceuticals, Inc.

Industry Context

StockSavvy.ai notes that executive departures and associated separation agreements are common events in the pharmaceutical and biotech sectors, often occurring during periods of strategic review or transition. The terms of such agreements can provide insights into the company's financial health and its approach to managing leadership changes.

Management Changes

Stakeholder Impact

• Shareholders: The departure of a CEO can create uncertainty, but the clear separation agreement may mitigate immediate concerns.
• Employees: Leadership transition may lead to a period of adjustment and potential shifts in company direction.
• Creditors: The financial terms of the separation agreement are disclosed, providing transparency on cash outflows.

Next Steps

• The company will continue to operate under an interim CEO.
• The company will fulfill the terms of the separation agreement with Dr. Lbiati.

Key Dates

Keywords

Hepion Pharmaceuticals, 8-K Filing, CEO Resignation, Separation Agreement, Executive Departure, Corporate Governance, Dr. Kaouthar Lbiati, Severance Package